Form 4: Baxter CEO Hider Receives Significant Equity Grant

Baxter International's President and CEO, Andrew P. Hider, was granted 201,804 restricted stock units and 488,506 stock options as part of his compensation.

Summary

• Andrew P. Hider, President and CEO of Baxter International Inc. (BAX), received a grant of 201,804 restricted stock units (RSUs) on February 27, 2026.
• The RSUs were granted at a price of $0 and are scheduled to vest in three equal annual installments beginning on March 1, 2027, subject to vesting requirements of the Amended and Restated Baxter International Inc. 2021 Incentive Plan.
• Hider also received a grant of 488,506 stock options on February 27, 2026, with an exercise price of $20.37.
• These stock options become exercisable in three equal annual installments beginning on March 1, 2027, and have an expiration date of February 27, 2036.
• Following these transactions, Andrew P. Hider beneficially owns 572,239 shares of common stock, which includes automatic reinvestment of dividends and shares held in Baxter's Employee Stock Plan.
• Hider also beneficially owns 488,506 derivative securities in the form of stock options.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it signifies continued executive commitment and aligns the CEO's long-term financial interests with shareholder value through equity-based compensation.

Positives

• The equity grants align the CEO's long-term financial interests with those of shareholders, incentivizing sustained performance.
• The grants are part of a standard executive compensation package, indicating continued commitment from the CEO to the company's future.

Negatives

• The grants do not represent an immediate cash investment by the CEO, as they were granted at a $0 price for RSUs and require future exercise for options.
• The vesting schedule means the full benefit of the grants is not immediate and is contingent on future employment and potential performance conditions.

Risks

• The value of the restricted stock units and stock options is subject to the future market performance of Baxter International's common stock.
• Failure to meet the vesting requirements set forth in the 2021 Incentive Plan could result in forfeiture of the unvested awards.
• The stock options carry the risk that the stock price may not exceed the exercise price of $20.37 by the expiration date, rendering them worthless.

Future Outlook

The vesting schedules for both the restricted stock units and stock options extend several years into the future, indicating a long-term incentive structure for the CEO tied to the company's sustained performance and stock appreciation.

Industry Context

StockSavvy.ai notes that equity-based compensation, such as restricted stock units and stock options, is a prevalent and standard practice across the healthcare industry for executive remuneration. This approach is designed to align the interests of top management with long-term shareholder value creation, a common theme in publicly traded companies.

Comparison to Industry Standards

• Executive equity grants, such as restricted stock units and stock options, are a standard component of compensation packages for CEOs in large-cap healthcare companies like Baxter International. This practice is consistent with global benchmarks for aligning executive incentives with long-term shareholder value.
• For instance, similar structures are observed at peers such as Medtronic (MDT) or Abbott Laboratories (ABT), where a significant portion of executive pay is tied to performance-based equity awards.

Corporate Governance

Related Party Transactions

• The grant of restricted stock units and stock options to Andrew P. Hider, the President and CEO, constitutes a related party transaction. This is a standard practice for executive compensation and is disclosed as required by SEC regulations.

Stakeholder Impact

• Shareholders: The equity grant aligns the CEO's long-term interests with shareholder value creation, potentially incentivizing strong company performance.
• Employees: No direct impact on general employees, but reflects the company's compensation strategy for its top executives.

Next Steps

• The restricted stock units are scheduled to vest in three equal annual installments beginning March 1, 2027.
• The stock options will become exercisable in three equal annual installments beginning March 1, 2027.

Key Dates

Recommendation

This Form 4 filing details a routine equity compensation grant to Baxter International's CEO. While it demonstrates continued executive commitment and aligns interests, it does not present new operational performance data, strategic shifts, or financial results that would fundamentally alter the investment thesis for BAX. Therefore, a "hold" recommendation is appropriate, maintaining current positions based on broader company fundamentals and market conditions rather than this specific insider transaction.

Keywords

BAX, Baxter International, Andrew Hider, Form 4, SEC filing, restricted stock units, stock options, executive compensation, equity grant, insider transaction